Lupin Limited has notified stock exchanges of the launch of Dasatinib Tablets in the United States following approval from the US Food and Drug Administration.
Developed in collaboration with Pharmascience Inc., the product marks an addition to Lupin’s oncology offerings in a key global market and aligns with the company’s focus on complex generics.
On February 2, 2026, Lupin Limited made a disclosure under Regulation 30 of the SEBI Listing Regulations, informing the National Stock Exchange of India and BSE Limited about the launch of Dasatinib Tablets in the US.
The disclosure was accompanied by an official press release for public dissemination.
The launch follows the approval of Lupin’s Abbreviated New Drug Application by the US FDA. Dasatinib Tablets have been introduced in multiple strengths ranging from 20 mg to 140 mg and were developed in partnership with Pharmascience Inc., a Canada-based pharmaceutical manufacturer.
Dasatinib Tablets are bioequivalent to Sprycel® by Bristol-Myers Squibb Company. The product is indicated for the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia across various disease phases, as well as Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Approved use includes both adult patients and paediatric patients aged one year and above, subject to specific clinical conditions.
According to industry data, the reference listed drug Sprycel® recorded estimated annual sales of approximately USD 930 million in the United States for the twelve months ended October 2025. This provides context to the size of the therapeutic segment in which Lupin’s product has been launched.
The product was developed jointly with Pharmascience Inc., which has a global presence and supplies medicines to over 50 countries.
The collaboration combines Lupin’s experience in complex generics with Pharmascience’s manufacturing and international distribution capabilities.
Lupin Limited is a Mumbai-headquartered pharmaceutical company with operations spanning more than 100 markets. Its portfolio includes branded and generic formulations, biotechnology products and active pharmaceutical ingredients, supported by a global manufacturing and research footprint.
On February 2, 2026, Lupin’s shares were trading at ₹2,130.40, reflecting a marginal decline from the previous close. During the trading session, the stock moved between a low of ₹2,078.20 and a high of ₹2,148.00.
Read More: Union Budget 2026 Highlights: Your 5-Minute Guide to Fiscal, Tax and Sectoral Measures.
The launch of Dasatinib Tablets in the United States represents a regulatory and commercial milestone for Lupin within the oncology segment. While market impact will depend on competitive and pricing dynamics, the development underscores the company’s continued engagement in regulated global markets through partnerships and complex generic offerings.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Feb 2, 2026, 3:23 PM IST
Neha Dubey
Neha Dubey is a Content Analyst with 3 years of experience in financial journalism, having written for a leading newswire agency and multiple newspapers. At Angel One, she creates daily content on finance and the economy. Neha holds a degree in Economics and a Master’s in Journalism.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
